Cited by 99Heart Failure Treatment and ManagementAtrial Fibrillation Management and OutcomesPhytochemistry and Bioactive Compounds

Clinical Use of Digitalis: A State of the Art Review

Whayne, Thomas F.·2018·American Journal of Cardiovascular Drugs

Abstract

The history of digitalis is rich and interesting, with the first use usually attributed to William Withering and his study on the foxglove published in 1785. However, some knowledge of plants with digitalis-like effects used for congestive heart failure (CHF) was in evidence as early as Roman times. The active components of the foxglove (Digitalis purpurea and Digitalis lanata) are classified as cardiac glycosides or cardiotonic steroids and include the well-known digitalis leaf, digitoxin, and digoxin; ouabain is a rapid-acting glycoside usually obtained from Strophanthus gratus. These drugs are potent inhibitors of cellular membrane sodium-potassium adenosine triphosphatase (Na+/K+-ATPase). For most of the twentieth century, digitalis and its derivatives, especially digoxin, were the available standard of care for CHF. However, as the century closed, many doubts, especially regarding safety, were raised about their use as other treatments for CHF, such as decreasing the preload of the left ventricle, were developed. Careful attention is needed to maintain the serum digoxin level at ≤ 1.0 ng/ml because of the very narrow therapeutic window of the medication. Evidence for benefit exists for CHF with reduced ejection fraction (EF), also referred to as heart failure with reduced EF (HFrEF), especially when considering the combination of mortality, morbidity, and decreased hospitalizations. However, the major support for using digoxin is in atrial fibrillation (AF) with a rapid ventricular response when a rate control approach is planned. The strongest support of all for digoxin is for its use in rate control in AF in the presence of a marginal blood pressure, since all other rate control medications contribute to additional hypotension. In summary, these days, digoxin appears to be of most use in HFrEF and in AF with rapid ventricular response for rate control, especially when associated with hypotension. The valuable history of the foxglove continues; it has been modified but not relegated to the garden or the medical history book, as some would advocate.

Integrity signals

Registry

Crossref · 10.1007/s40256-018-0292-1

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

3 of the 133 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Whayne, T. F.
Affiliations
University of Kentucky (US)
Corresponding author
Whayne, Thomas F.
Venue
American Journal of Cardiovascular Drugs
Published
2018-07-31
Volume
18
Issue
6
Pages
427-440
ISSN
  • 1175-3277 (ISSN-L)
  • 1179-187X
OpenAlex
W2886362585
Cited by
99
References
133
Citations by year
2026: 8 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 23 · 2021: 13 · 2020: 13 · 2019: 5
FWCI
1.44
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Cardiovascular Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Physical Sciences › Materials Science › Biomaterials › Phytochemistry and Bioactive Compounds
Keywords
digitalis, digoxin, cardiac glycosides, congestive heart failure, heart failure with reduced ejection fraction, atrial fibrillation, rate control, sodium-potassium ATPase inhibition, therapeutic drug monitoring, ouabain, digitoxin, hypotension
MeSH terms
ST Elevation Myocardial Infarction, Sodium-Potassium-Exchanging ATPase, Age Factors, Atrial Fibrillation, Body Weight, Cardiotonic Agents, Digitalis, Digitalis Glycosides, Digoxin, Drug Interactions, Heart Failure, Humans, Neoplasms, Ouabain, Plant Extracts, Sex Factors, Stroke Volume, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Drug Monitoring, Renal Insufficiency, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review